HRQOL) in each of the domains. With multivariate analysis, these differences maintained their significance (mean domain scores were higher by 2.5, 2.8, 2.8, 1.3 points, respectively, all p<0.0001). In itemlevel analysis, patients prescribed potassium citrate were less likely than those not prescribed it to report any nausea, stomach upset or cramps (43% vs 55%, p<0.001). Multivariate logistic regression showed a 40% lower likelihood of having GI complaints among patients prescribed potassium citrate, p¼0.001, when controlling for the aforementioned factors.
INTRODUCTION AND OBJECTIVES: Current American Urological Association (AUA) guidelines do not discuss recommendations in obtaining a stone analysis when a bilateral stone procedure is performed. To date, there is a limited amount of data surrounding discordant stone analysis when performing a simultaneous bilateral stone procedure. Stone analysis results, as well as 24-hour urinalysis are utilized for the medical management of stone disease and could possibly be misrepresented if conflicting stone analysis results were present. Therefore, we aim to describe the rate of discordant stone analysis results in patients undergoing ureteroscopy.
METHODS: A retrospective chart review was performed for all patients undergoing bilateral ureteroscopy with stone removal by a single surgeon at a single hospital between 2013 and 2016. All stones were analyzed at a single stone analysis laboratory using Fourier transform infrared spectroscopy (Beck labs, Indianapolis IN). Stones were then classified unilaterally based upon the dominant present (>50%). The only exception was for brushite where the presence of any brushite led to classification as a brushite stone former. 24-hour urinalysis results were reviewed and statistical analysis performed comparing discordant and concordant patient populations, assessing significant differences that would influence clinical management.
RESULTS: We identified 89 patients (178 renal units) who had bilateral stones removed at the time of ureteroscopy. The majority of stones were classified as calcium oxalate (CaOx) (59.4%) followed by CaP (30.6%), uric acid (UA) (3.9%), brushite (3.9%) and cystine (2.2%). Discrepancies in stone classifications were present 22% of the time. Evaluation of 24-hour urinalysis results demonstrated striking differences between those with conflicting and similar stone analysis results. Those patients with CaOx:CaP stone discordance compared to CaOx:CaOx concordant stone formers were more likely to have an elevated pH (p<0.001), calcium phosphate supersaturation (p<0.01) and lower uric acid supersaturation (p¼0.02).
CONCLUSIONS: Discrepancies in stone classifications are common in patients with bilateral stone disease. When metabolic evaluation was performed in these patients there were significant differences between discordant and concordant groups, especially CaOx only and CaOx:CaP stone formers. Thus, a single stone analysis in the setting of bilateral stone disease is insufficient and may lead to mismanagement when it is utilized in addition to 24-hour urinalysis results.
Source of Funding: None
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THE METABOLIC SYNDROME AND ITS IMPACT ON CALCIUM OXALATE STONE TYPE Egor Parkhomenko*, Kathleen Kan, Timothy Tran, Julie Thai, Kyle Blum, Mantu Gupta, NY, NY INTRODUCTION AND OBJECTIVES: The metabolic syndrome plays an important role in lithogenesis of calcium oxalate stones, but to our knowledge no study has clinically correlated metabolic factors that influence stone subtype. It has been indicated that calcium oxalate monohydrate (COM) stones are more likely of tubular origin as secondary deposits onto calcium apatite whereas calcium oxalate dihydrate (COD) stones are more likely to form in solution. We sought to perform a comprehensive analysis of metabolic and clinical factors in patients who make predominantly one type of calcium oxalate stone.
METHODS: From our prospectively maintained database of 1049 kidney stone formers between 01/2014 -06/2016, we identified 95 patients with comprehensive medical records including stone analysis who had predominantly (!80%) COM (75 pts) or COD (20 pts) composition. Another 27 patients had mixed COM and COD stones (<80% of one subtype). Clinical, demographic and laboratory parameters were compared between (>80%) COM or COD stones.
RESULTS: There were no differences in age, gender or BMI between the COM and COD patients. COM patients were more likely to be hypertensive (46.7% vs. 15% p¼0.01) and this difference was more pronounced in males (60% vs. 16.7%, p¼0.007). Male COM patients were also more likely to be diabetic (22% vs. 0%, p¼0.102). There were no differences in hyperlipidemia, coronary artery disease, gastrointestinal disease, and serum markers of uric acid, calcium, creatinine or HbA1c. COM patients were more likely to have hypocitraturia compared to COD patients (49.3% vs. 25%, p ¼ 0.05). Male COM patients had significantly higher urinary oxalate levels (48 vs. 37 mg/d, p¼0.05) compared to male COD formers. COD females showed a trend towards higher calcium levels vs. COM females (213 vs. 140 mg/d, p¼0.13). The calcium/oxalate ratio in COD formers was significantly higher compared to COM formers (6.46 vs. 4.84, p < 0.05). No differences were observed for urine uric acid levels, supersaturation of uric acid, CaOx supersaturation, magnesium, and pH.
CONCLUSIONS: Our study suggests that HTN and DM, two components of the metabolic syndrome, are more closely linked to COM stones compared to COD stones. Patients with higher urine oxalate and lower urine citrate levels tend to form COM stones, while those with a higher urine calcium/oxalate ratio tend to form COD stones. This suggests that the two stone subtypes are clinically and metabolically different and thus may have different etiology. 
Source of
INTRODUCTION AND OBJECTIVES:
Cystinuria is a rare systemic genetic disease caused by a defect in an amino acid transporter which results in elevated urinary cystine excretion and severe recurrent stone disease. Interestingly, a subset of patients consistently forms stones unilaterally, despite no evidence of anatomic differences between their two kidneys. This study aimed to determine if bilateral cystine stone formers had different clinical outcomes compared to unilateral stone formers and whether thiola use impacted these outcomes.
METHODS: This was a retrospective case-control study for all cystine stone patients evaluated and treated at the University of Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 THE JOURNAL OF UROLOGY â e1213
California, San Francisco between 1994 and 2015. The presence of unilateral (only formed stones in one kidney alone during their entire lifetime) versus bilateral (formed stones in both kidneys at some point in their lifetime) stone disease was determined with review of all imaging studies, radiology reports, and clinic notes. Demographic data, clinical presentation, current medical treatment and overall renal function were compared between the two groups. RESULTS: 42 cystine stone patients were identified and included in the analysis. Mean age at first presentation was 21.7AE14.0 years (mean current age 44.2AE19.7 years) with women representing 52.4% of all cases. Most patients presented with flank pain (62.1%) following by recently passed stone (24.1%). Of the 42 patients, 28 patients (66.7%) had bilateral stone disease, while 9 patients (21.4%) only experienced left sided stones, and 5 patients (11.9%) right side stones. Bilateral stone formation did not correlate to gender (p ¼ 0.38), age of first presentation (p ¼ 0.89), or family history of stone disease (p ¼ 0.32). Thiola was used by 21.4% of patients with unilateral disease and 35.7% of patients with bilateral disease (p ¼ 0.32). Bilateral cystine stone formation was significantly associated with a higher number of lifetime stone surgeries (7.5 versus 3.7 sessions, p <0.05). Despite this increased number of surgeries for patients with bilateral disease, thiola use and current serum creatinine level (1.05 versus 0.94 mg/dL, p ¼ 0.38) were not significantly different between the two groups.
CONCLUSIONS: The majority of cystinuric patients will form stones bilaterally during their lifetime, and require more surgical interventions than those who only form cystine stone on one side. Despite this, overall renal function (via serum creatinine level) is still well preserved in bilateral and unilateral cystine stone formers and thiola use may not impact laterality or severity of disease. 
Source of Funding
INTRODUCTION AND OBJECTIVES:
The influence of obesity on the effectiveness of KCit to reduce calcium stone risk is not wellcharacterized. We evaluated 24h urinary risk factors in both obese (BMI ! 30) and non-obese stone formers (SFs) and compared treatment-associated changes after starting KCit. As there is a concern for forming calcium phosphate (Ca Phos) stones while taking KCit, brushite relative saturation (RS) and pH changes were also assessed.
METHODS: With IRB approval, we identified 78 known mixedcalcium SFs from an institutional database (n¼78; M:F 34:44; age, 54AE15 y; BMI, 31AE9). Patients were included in this retrospective analysis if they had stone comprised of >50% calcium and 24-hr urine assays within 3 years before and after initiating KCit, and if BMI at the time of collection was documented. RS indices were calculated with Equil2. Patients were divided into non-obese stone formers (NOSF, BMI<30) and obese stone formers (OSF, BMI ! 30). Pre-and post-KCit 24-h urinary parameters were examined using univariate and multivariate analyses with BMI as a covariate. To control for multiple statistical comparisons, the Bonferroni correction revealed that a p value <0.003125 was required for significance.
RESULTS: Baseline 24-h urine values were similar in both groups, though OSF had a higher uric acid RS (1.45 vs 0.60, p¼0.002), likely due to more acidic urine (pH 5.8 vs 6.3, p¼0.009). Significant increases in urine potassium in both groups suggested KCit compliance (NOSF: +13, p¼0.001; OSF: +28, p<0.0001). Both NOSF and OSF had statistically significant increases in urine citrate (233 to 286, p¼0.003; 289 to 575, p<0.0001) and pH (6.3 to 6.6, p¼0.001; 5.8 to 6.5, p<0.0001). Post therapy brushite RS was similar in NOSF and OSF (1.85 vs 1.53, p¼0.894) and did not exceed the risk cutoff of 2.0. BMI correlated directly with changes in urine calcium and citrate in OSF but not NOSF (-5 vs +17 mg/day, p¼0.003; and +63 vs +273, p¼0.001, respectively). Changes in urine pH and brushite RS were similar between groups.
CONCLUSIONS: Both obese and non-obese calcium SFs experienced favorable changes in urine pH and citrate excretion. However, obese patients were more likely to achieve normocitraturia. Neither group had significant changes in brushite RS while using KCit, perhaps alleviating concerns of CaPhos risk.
